Arena Enters Strategic Partnership With Everest

San Diego – December 8, 2017 – Cooley advised Arena Pharmaceuticals on a development and commercialization partnership with Everest Medicines for two product candidates in mainland China, Taiwan, Hong Kong, Macau and South Korea.

The product candidates are ralinepag – for the treatment of pulmonary arterial hypertension – and etrasimod, which is being evaluated for multiple autoimmune diseases, including ulcerative colitis, a form of inflammatory bowel disease. C-Bridge Capital has invested $50 million to fund Everest and has assembled a veteran team to rapidly advance product candidates towards approval and launch.

“We are very pleased to establish a partnership with Everest and C-Bridge Capital around two of our potential best-in-class product candidates,” said Amit D. Munshi, president and CEO of Arena, in a news release. “With new regulations in place in China to expedite approvals, a significant opportunity for ralinepag and etrasimod exists in early synchronization of development programs.”

Arena, which trades on The Nasdaq Global Select Market under the symbol "ARNA," is a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.

Cooley partner Kay Chandler and special counsel Rena Kaminsky lead the team advising Arena.

Cooley previously advised Arena on its amended agreement with Eisai, a Japanese pharmaceutical company, in early 2017.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.